MedTrace Logo

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

NCT03379051 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2022-08-22

No results posted yet for this study

Summary

Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL

Conditions

Interventions

DRUG

Venetoclax

BCL-2 Inhibitor

DRUG

Umbralisib

PI3K-Delta Inhibitor

BIOLOGICAL

Ublituximab

Glycoengineered Anti-CD20 mAb

DRUG

Lenalidomide

Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties

Sponsors & Collaborators

  • James P. Wilmot Cancer Center

    collaborator OTHER

  • TG Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Paul Barr, MD · Wilmot Cancer Institute - University of Rochester

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-27
Primary Completion
2022-05-26
Completion
2022-06-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03379051 on ClinicalTrials.gov